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Effects of β2-adrenergic receptor polymorphisms on asthma severity and 
response to salbutamol in Egyptian children  
 
INTRODUCTION 
Asthma is a disease characterized by hyper-
responsiveness of the airways to various stimuli, 
which results in airway obstruction that is reversible 
either spontaneously or as a result of treatment1. 
Asthma prevalence has increased very considerably 
in recent decades such that it is now one of the 
commonest chronic disorders in the world2. Asthma 
is estimated to affect 300 million people world-
wide, with an expected increase to 400 million 
worldwide by 20253. In a recent Egyptian study, the 
overall prevalence of wheezing in the last year was 
14.7% and of physician-diagnosed asthma was 
9.4%4. 
Asthma aggregates within families and is a 
complex multifactorial disease with the 
involvement of environmental and genetic 
components5. Understanding of the genetic basis of 
asthma may contribute toward identifying better 
targets for asthma drugs6. 
Inhaled β2-adrenergic agonist medications are 
the foundation of therapy for acute asthma 
exacerbation7. The β2-adrenergic receptor 
(ADRB2) protein is expressed on bronchial smooth 
muscle cells and mediates physiologic responses 
including bronchodilation, vasodilatation and 
lipolysis8.  ADRB2 gene located on chromosome 
5q31-32 is one of the candidate genes most 
consistently identified as being associated with 
asthma-related phenotypes 9. 
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Several polymorphisms of ADRB2 have been 
described in particular at codons 16 
Arginine/Glycine and 27 Glutamine /Glutamic acid 
which alter the receptor function in vitro10,11. In 
adults, genetic variations in this receptor have been 
linked to asthma severity12, bronchial hyper-
responsiveness13 and lung function tests14. 
The relationship between ADRB2 genotypes 
and response to inhaled β2-adrenergic agonists is 
controversial. Some studies15-21 have found that the 
Arg/Arg genotype is associated with reduced 
response to these medications, whereas others22-25 
have found that the Gly/Gly genotype is associated 
with reduced response. 
Knowledge of the genotype which is 
associated with favorable response, could 
significantly affect treatment selection for asthma in 
children. The current study will focus on the 
polymorphisms of ADRB2 gene at codon 16 as a 
previous study22 found no association between 
polymorphisms at position 27 and response to 
inhaled β2-adrenergic agonists in asthmatic 
children. 
So, the objectives of this study were to assess 
the frequencies of ADRB2 polymorphisms at codon 
16 in Egyptian asthmatic children and the effects of 
these polymorphisms on asthma severity and 
bronchodilator response to salbutamol. 
 
METHODS 
This case-control study was conducted at 
pulmonology unit, Zagazig University children's 
hospital during the period from December 2010 to 
December 2011. One hundred children were 
enrolled in the study. They were divided into two 
groups; Group I and Group II.  
Group I (asthmatic group) included 50 
children, 26 males and 24 females. Their ages 
ranged from 5-12 years with a mean value of 6.8 
years. The diagnosis of asthma in these patients was 
based on National Asthma Education and 
Prevention Program Guidelines26. Cases were 
classified and subgrouped as follow: mild 
intermittent and mild persistent asthmatics were 
included into the group of mild asthma and 
moderate persistent and severe persistent asthmatics 
were included as the group of moderate/severe 
asthma. Recruited asthma patients were not in 
exacerbation state and did not have other 
concomitant diseases that might affect lung 
function. Children with any chronic disease (other 
than asthma) were excluded. 
 Group II (control group) included 50 healthy 
children, 26 males and 24 females. Their ages 
ranged from 5-12 years with a mean value of 7.2 
years. Subjects were included as controls only if 
they reported no history of asthma or allergies, no 
history or report of having experienced symptoms 
of coughing, wheezing and shortness of breath in 
the past 2 years and no other history of lung 
diseases, chronic illnesses, or medications.  
For all study groups, detailed history taking, 
systematic physical examination, chest x-ray, 
pulmonary function testing and ADRB2 genotyping 
were performed. Informed consent was obtained 
from the children’s guardians. The study protocol 
was approved by the Pediatric Department Ethics 
Committee of Zagazig University. 
ADRB2 genotyping: 
Three milliliters of venous blood were collected 
aseptically from every subject in a tube containing 
EDTA. This blood was incubated at -20°C 
temperature. After samples were enough, the blood 
was prepared for DNA extraction and amplification. 
DNA extraction was done using Axyprep Blood 
Genomic DNA Miniprep Kit (Axygen Biosciences, 
USA). DNA amplification was carried out by using 
polymerase chain reaction (PCR) Master-Mix Gold 
beads (Bioron, Germany). The nucleotide 




Then, for detection of the ADRB2 polymorphisms, 
restriction fragment assay was done. 
Pulmonary function testing: 
Pulmonary function tests were performed using 
Lilly Pneumatocho- graph (D-97204 Hochberg, 
Germany). Spirometry was performed according to 
the American Thoracic Society standards27. 
Spirometeric measurements included forced 
expiratory volume in one second (FEV1), forced 
vital capacity (FVC) and peak expiratory flow 
(PEF).   
Pulmonary function test results were expressed 
as a percentage of the predicted normal value. 
Asthmatic children were instructed to stop any 
systemic bronchodilator or corticosteroid therapy 
72 hours before tests and short acting β2-adrenergic 
agonists were stopped 12 hours before the 
procedure. 
To assess response to a bronchodilator in 
asthmatic group, one dose of salbutamol (0.15 
mg/kg) was administered using ultrasonic nebulizer 
(eMed A100, Italy) and measurement of lung 
function was performed before and 15 minutes after 
salbutamol nebulization. Response to salbutamol 
was reported as a percent change in FEV1 between 
baseline and after salbutamol administration. We 
chose to explore changes in FEV1 after salbutamol 
ADRB2 polymorphisms in asthmatic children 
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mobilizations as a measure of response to a 
bronchodilator, because this was the most objective, 




Data were analyzed using Statistical Package for 
Social Sciences (SPSS), release 16. The 
quantitative variables were expressed as means and 
standard deviations. For comparison between two 
group means, t-test was used. For comparison 
between three group means, one way ANOVA 
(analysis of variance) was used. Qualitative 
variables were expressed by frequency and 
percentage and compared using chi-square test. 
Also, odds ratio (OR) and 95% confidence interval 
(CI) were calculated. For all tests a probability (P) 
less than 0.05 was considered significant and less 
than 0.001 was considered highly significant. 
 
RESULTS 
The characteristics of the two study groups are 
shown in table 1. The two groups were similar in 
age and gender. A highly significant difference was 
observed in spirometric parameters between 
asthmatic and healthy children (P<0.001). Also, 
significant difference was observed in genotype 
distribution between asthmatic and healthy children 
(P<0.05). 
Distribution of ADRB2 gnenotypes at codon 
16 among asthmatic and non-asthmatic children is 
illustrated in table 2. There was a significant 
increase of carriers of Arg/Gly and Gly/Gly 
genotypes among asthmatic children in comparison 
to controls (OR = 7.9; CI: 0.94 - 67.4, P<0.05 and 
OR= 4.5; CI: 0.91-22.7, P<0.05 respectively). On 
the other hand, there was a lower frequency of 
Arg/Arg genotype in asthmatic children than in 
controls (OR = 0.14; CI: 0.04- 0.55, P<0.05). 
Relation between polymorph-isms of ADRB2 
at codon 16 and asthma severity is shown in table 3. 
Statistical analysis revealed an association of   
Arg/Arg genotype with mild asthma (OR= 5.77; 
95% CI: 1.55-21.5, P<0.05). On other hand, 
Gly/Gly genotype was less frequent in mild asthma 
(OR= 0.057; 95% CI: 0.006-0.516, P<0.05). 
However, no difference in distribution of Arg/Gly 
genotype was noticed among mild and 
moderate/severe asthmatics (OR=0.79; 95% CI: 
0.156-3.99, P> 0.05). 
Regarding bronchodilator responsiveness, 
Gly/Gly and Arg/Gly genotypes were associated 
with reduced response (FEV1 change =11.4% and 
9.1%, respectively), while Arg/Arg genotype was 
associated with favorable response (FEV1change = 
17.3%) (Table 4). 
 
Table 1. Demographic and clinical data of the study groups. 
Variable Asthmatic group  
(n = 50) 
Control group 
(n = 50)  
test P value 
Age( year) , Mean ±SD 6.8±2.54 7.2±2.08 0.86 >0.05 
Male gender, n (%)  26 (52%) 26 (52%) 0.0 >0.05







































Asthma severity, n (%) 
Mild intermittent 
Mild persistent 
























Table 2. Distribution of ADRB2 genotypes at codon 16 in asthmatic and healthy children. 
Genotype 
Asthmatic group 
(n = 50) 
Control group 
(n = 50)  
OR 95% CI P 
Arg/Arg 35 (70%) 47 (94%) 0.14 (0.04 - 0.55) <0.05 
Arg/Gly 7 (14%) 1(2%) 7.9 (0.94 - 67.4) <0.05 
Gly/Gly 8 (16%) 2(4%) 4.5 (0.91 - 22.7) <0.05 
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Table 3. Relation between polymorphisms of  β2AR at codon 16 and asthma severity. 
Genotype 
Mild asthma  
(n =31) 
Moderate/ 
severe asthma  
(n =19) 
OR 95% CI P 
Arg/Arg 26 (83.8%) 9 (47.3%) 5.77 1.55-21.5) < 0.05 
Arg/Gly 4 (13%) 3( 15.7%) 0.79 0.156-3.99) > 0.05 
Gly/Gly 1 (3.2%) 7 (37 %) 0.057 0.006-0.516 < 0.05 
 
Table 4. Relation between polymorphisms of  β2AR at codon 16 and response to salbutamol 
nebulization. 
 Arg/Arg 





P1 P2 P3 
Percentage of change  
of FEV1 (%), Mean±SD 
17.3±7.9 9.1± 3.6 11.4 ±2.1 <0.05a <0.05b >0.05c 
FEV1: forced expiratory volume in one second ,   a  Arg/Arg group vs. Arg/Gly group  ,  
 b Arg/Arg group vs. Gly/Gly group, c Arg/Gly group vs. Gly/Gly group 
 
DISCUSSION 
Genetic assessment revealed that asthmatic children 
had frequencies of Arg/Arg of 70%, Arg/Gly of 
14%, and Gly/Gly of 16%, while in the healthy 
children the frequency of Arg/Arg was 94%, 
Arg/Gly was 2%, and Gly/Gly was 4%. These 
results revealed a significant difference of 
distribution of ADRB2 genotypes at codon 16 
among asthmatics and healthy children. 
Globally, there are marked interethnic 
differences in the frequency of ADRB2 
polymorphisms. In Caucasian–American and 
African–American healthy individuals, the Arg/Gly 
genotype was the most predominant (38.3% and 
50.4%   respectively), while Arg/Arg genotype was 
present in lower frequencies (26.6% and   23.6%, 
respectively)28. In another study conducted on 128 
Chinese asthmatics by Wang et al., the frequency of 
Arg/Arg was 40.6%, Arg/Gly was 42.2%, and 
Gly/Gly was 17.2%, while in the healthy people the 
frequency of Arg/Arg was 27.9%, Arg/Gly was 
47.1%, and Gly/Gly was 25.0% 29. 
In Egyptian population, Salama et al.30 found 
that the frequencies of ADRB2 genotypes at 
position 16 among healthy children, was 52.6% for 
Arg/Arg, 5.3% for Arg/Gly and 42.1% for Gly/Gly. 
In asthmatic children, these genotype frequencies 
were different; 17.5% for Arg/Arg, 45% for 
Arg/Gly and 37.5% for Gly/Gly. Although these 
frequencies were different from our results, yet the 
final conclusion was the same:  higher frequencies 
of Arg/Gly and Gly/Gly genotypes in asthmatic 
children when compared with controls. In another 
study, the frequencies of ADRB2 genotypes at 
position 16 among Egyptian healthy individuals, 
was 32.6% for Arg/Arg, 49% for Arg/Gly and 
18.5% for Gly/Gly31. These differences reflect the 
need for wide-based, population studies. 
There was an association of Arg/Arg genotype 
with mild asthma when compared with 
moderate/severe asthma. On the other hand, 
Gly/Gly genotype was associated with 
moderate/severe asthma when compared with mild 
asthmatics. This indicates that the polymorphism at 
codon 16 of ADRB2 is a possible determinant of 
asthma severity. 
A meta-analysis including a total of 28 studies 
performed by Contopoulos-Ioannidis et al.32, 
concluded that, Gly/Gly had a much higher risk for 
nocturnal asthma and asthma severity than the 
Arg/Arg. 
In contrast, Salama et al.30 found an association 
between Arg/Gly genotype with severe asthma 
when compared to mild/moderate asthma. Also, 
Gly/Gly genotype was present with lower 
frequencies in severe asthma when compared with 
mild/moderate asthma.  
In vitro functional studies33,34 indicated that 
down-regulation of ADRB2 receptors occurs in 
individuals expressing Gly16 allele in response to 
circulating catecholamines or exogenously 
administered β2-agonists. The Arg16 allele, which 
demonstrates resistance to down-regulation, might 
therefore be expressed at greater levels than the 
Gly16 allele within airways. Accordingly, 
individuals carrying the Gly/Gly genotype might be 
more sensitive to stimuli resulting in 
bronchoconstriction, and therefore have more 
reactive airways than individuals carrying the 
Arg16 allele.  
In our study, the Gly allele (Arg/Gly and 
Gly/Gly genotypes) was associated with resistance 
to the bronchodilator effect of inhaled short-acting 
β 2-agonist (salbutamol) when compared with 
Arg/Arg genotype. The association between 
ADRB2 genotypes and response to inhaled β2 
agonists is controversial, and discordant findings 
have been reported. Finkelstein et al.22 conducted a 
meta-analysis to examine the association between 
ADRB2 polymorphisms and the response to inhaled 
ADRB2 polymorphisms in asthmatic children 
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β2 -adrenergic agonists in children with asthma. 
They included 3 studies9,35,36 and found a significant 
association between favorable therapeutic response 
to inhaled β2-adrenergic agonists and the Arg/Arg 
genotype. Several studies came up with the same 
conclusion23-25.  
However, when examining the influence of 
ADRB2 polymorphisms on the response to long-
term and repeated dosages of inhaled β2 -adrenergic 
agonist therapy, the Arg/Arg genotype has been 
more closely associated with reduced response15-20. 
Moreover, in children with severe asthma 
exacerbations, Carroll et al.21   found that children 
whose genotypes were Gly/Gly had a more rapid 
response to inhaled β2 -adrenergic agonists. 
Five reasons may underlie the somewhat 
discordant results reported by different authors. 
First, studies had included different patient 
populations, regarding age, disease severity, and 
ethnic background. Second, authors had 
administered different β2-agonists to study patients. 
Third, authors had used different outcome measures 
and endpoints to assess drug-responsiveness. 
Fourth, some authors had suggested that the 
conflicting results among studies could be 
explained by specific combinations of 
polymorphisms that are commonly inherited 
together (ADRB2 haplotypes), rather than by a 
single allele polymorphism37.   Finally, race is both 
a biologic and a social construct and constitutes not 
only genetic differences in individuals, but also the 
behaviors, beliefs, and experiences that vary among 
races. 
In conclusion, genetic polymorphisms of 
ADRB2 gene at codon 16 may be a determinant of 
asthma severity and response to salbutamol in 
Egyptian asthmatic children.  However, we cannot 
exclude the possibility that other polymorphisms or 
complex haplotypes within the promoter and coding 
regions of the ADRB2 gene or adjacent genes 
might contribute to the present results. Further 
studies are needed to demonstrate effects of other 
polymorphisms of ADRB2 gene on asthma-related 




1. Weinberger M, Abu-Hasan M. Pseudo-asthma: 
when cough, wheezing, and dyspnea are not asthma. 
Pediatrics 2007; 120:855-64.   
2. Anandan C, Nurmatov U, van Schayck O, 
Sheikh A. Is the prevalence of asthma declining? 
Systematic review of epidemiological studies.  
Allergy 2010; 65(2): 152-67. 
3. Masoli M, Fabian D, Holt S, Beasley R. The 
global burden of asthma: executive summary of the 
GINA Dissemination Committee report. Allergy 
2004; 59:469-78.  
4. Georgy V, Fahim HI, El Gaafary M, Walters S. 
Prevalence and socioeconomic associations of asthma 
and allergic rhinitis in northern Africa. Eur Respir J 
2006; 28:756-62. 
5. Bijanzadeh M, Mahesh PA, Ramachandra NB. 
An understanding of the genetic basis of asthma. 
Indian J Med Res 2011; 134:149-61. 
6. Hall IP. The future of asthma. BMJ 1997; 
314(7073): 45–49.  
7. Baren JM, Zorc JJ. Contemporary approach to the 
emergency department management of pediatric 
asthma. Emerg Med Clin North Am 2002; 20:115–
38. 
8. Insel PA. Seminars in medicine of the Beth Israel 
Hospital, Boston. Adrenergic receptors-evolving 
concepts and clinical implications. N Engl J Med 
1996; 334:580–5. 
9. Silverman EK, Kwiatkowski DJ, Sylvia JS, 
Lazarus R,  Drazen JM, Lange C, et al. Family-
based association analysis of beta2-adrenergic 
receptor polymorphisms in the childhood asthma 
management program. J Allergy Clin Immunol 2003; 
112:870– 6. 
10. Giubergia V, Zelazko M, Roy A, Gravina LP, 
Gonzalez Pena H, Chertkoff L. Beta 2-adrenergic 
polymorphisms and total serum IgE levels in children 
with asthma from Argentina. Ann Allergy Asthma 
Immunol 2009;102(4):308–13. 
11. Qiu YY, Zhang XL, Yin KS . Association between 
beta 2-adrenergic receptor genetic polymorphisms 
and total serum IgE in asthmatic patients of Chinese 
Han nationality. Respiration 2006;73(2):180-4. 
12. Weir TD, Mallek N, Sandford AJ, Bai TR,  
Awadh N, Fitzgerald JM, et al. Beta2-Adrenergic 
receptor haplotypes in mild, moderate and fatal/near 
fatal asthma. Am J Respir Crit Care Med 1998; 
158:787–91. 
13. Hall IP, Wheatley A, Wilding P, Liggett SB. 
Association of Glu 27 beta 2-adrenoceptor 
polymorphism with lower airway reactivity in 
asthmatic subjects. Lancet 1995; 345: 1213– 4. 
14. Summerhill E, Leavitt SA, Gidley H, Parry 
R, Solway J, Ober C. Beta 2-Adrenergic receptor 
arg16/ arg16 genotype is associated with reduced 
lung function, but not with asthma, in the Hutterites. 
Am J Respir Crit Care Med 2000;162:599–602. 
15. Taylor DR, Epton MJ, Kennedy MA, Smith AD, 
 Iles S,  Miller AL, et al. Bronchodilator response 
in relation to β2-adrenoceptor haplotype in patients 
with asthma. Am J Respir Crit Care Med 2005; 
172:700 –3. 
Salah et al. 
86 
16. Lipworth BJ, Hall IP, Tan S, Aziz I, Coutie W. 
Effects of genetic polymorphism on ex vivo and in 
vivo function of the β2-adrenoceptors in asthmatic 
patients. Chest 1999; 115: 324-8. 
17. Israel E, Drazen JM, Liggett SB, boushey  HA, 
Cherniac  RM, Chinchilli  VM, et al. The effect of 
polymorphisms of the β2-adrenergic receptor on the 
response to regular use of albuterol in asthma. Am J 
Respir Crit Care Med 2000; 162:75– 80. 
18. Taylor DR, Drazen JM, Herbison GP, Yandava 
CN, Hancox RJ,  Town GI. Asthma exacerbations 
during long term-agonist use: influence of β2-
adrenoceptor polymorphism. Thorax 2000; 55:762–7. 
19. Israel E, Chinchilli VM, Ford JG, Boushey 
HA,  Cherniack R, Craig TJ. Use of regularly 
scheduled albuterol treatment in asthma: genotype-
stratified, randomized, placebo-controlled cross-over 
trial. Lancet 2004;364:1505–12. 
20. Palmer CA, Lipworth BJ, Lee S, Ismail 
T, Macgregor DF,  Mukhop-adhyay S. Arginine-
16 β-2 adrenoceptor genotype predisposes to 
exacerbations in young asthmatics taking regular 
salmeterol. Thorax 2006; 61:940 –4. 
21. Carroll CL, Stoltz P, Schramm CM, Zucker AR. 
Beta 2-adrenergic receptor polymorphisms affect 
response to treatment in children with severe asthma 
exacerbations. Chest 2009;135(5):1186-92. 
22. Finkelstein Y, Bournissen FG, Hutson JR, 
Shannon M. Polymorphism of the ADRB2 gene and 
response to inhaled beta-agonists in children with 
asthma: a meta-analysis. J Asthma 2009; 46:900–5. 
23. Kotani Y, Nishimura Y, Maeda H, Yokoyama M. 
β2-adrenergic receptor polymorphisms affect airway 
responsiveness to salbutamol in asthmatics. J Asthma 
1999; 36:583-90. 
24. Lima JJ, Thomason DB, Mohamed MH, Eberle 
LV, Self TH, Johnson JA. Impact of genetic 
polymorphisms of the β2-adrenergic receptor on 
albuterol bronchodilator pharmacodynamics. Clin 
Pharmacol Ther 1999; 65:519–25. 
25. Cho SH, Oh SY, Bahn JW, Choi JY, Chang 
YS, Kim YK, et al. Association between 
bronchodilating response to short-acting beta-agonist 
and non-synonymous single-nucleotide 
polymorphisms of beta-adrenoceptor gene. Clin Exp 
Allergy 2005;35:1162-7. 
26. National Asthma Education and Prevention Program. 
Expert Panel Report 3 (EPR-3): Guidelines for the 
Diagnosis and Management of Asthma-Summary 
Report 2007. J Allergy Clin Immunol 2007;120 : 
S94-138. 
27. American Thoracic Society. Standardization of 
spirometry, 1994 update. Am J Respir Crit Care Med 
1995; 152:1107–36. 
28. Xie HG, Stein CM, Kim RB. Frequency of 
functionally important β2 adrenoreceptor 
polymorphisms varies markedly among African–
American, Caucasian and Chinese individuals. 
Pharmacogenetics1999; 9:5-11. 
29. Wang  Z, Chen  C, Niu  T,  Wu D, Yang J, Wang 
B, et al. Association of Asthma with β2-Adrenergic 
Receptor Gene Polymorphism and Cigarette 
Smoking. Am J Respir Crit Care Med 2001; 163: 
1404- 9. 
30. Salama MS, Ashaat NA, Hamad AA. Genetic 
association between common beta-2 adrenoreceptor 
polymorphism and asthma severity in school-age 
children. Egyptian Journal of Medical Human 
Genetics; 12: 151-6. 
31. Hamdy S, Hiratsuka M, Narahar K, El-Enany 
M, Moursi N, Ahmed MS, et al. Allele and 
genotype frequencies  of  polymorphic  DCP1, CETP,  
ADRB2 and HTR2A in Egyptian population.  Eur J 
Clin Pharmacol 2002;58:29–36. 
32. Contopoulos-Ioannidis DG, Manoli EN, 
Ioannidis JP. Meta-analysis of the association of 
β2-adrenergic receptor polymorphisms with asthma 
phenotypes. J Allergy Clin Immunol 2005; 115:963–
2. 
33. Green SA, Turki, J, Innis, M, Liggett SB. Amino-
terminal polymorphisms of the human β2-adrenergic 
receptor impart distinct agonist-promoted regulatory 
properties. Biochemistry 1994;33: 9414- 9. 
34. Green SA, Cole G, Jacinto M, Innis M, Liggett 
SB. A polymorphism of the human β2-adrenergic 
receptor within the fourth transmembrane domain 
alters ligand binding and functional properties of the 
receptor. J Biol Chem 1993; 268: 23116-21. 
35. Martinez FD, Graves PE, Baldini M, Solomon 
S, Erickson R. Association between genetic 
polymorphisms of  the β2-adrenoceptor and response 
to albuterol in children with and without a history of 
wheezing. J Clin Invest 1997; 100: 3184 –8. 
36. Fu J, Chen H, Hu L, Zhang H, Ma Y, Chen Y. 
Association between the genetic polymorphisms of 
beta2-adrenergic receptor gene and the asthma 
susceptibility and clinical phenotypes in a Chinese 
population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 
2002; 19:41-45. 
37. Hung CC, Tai JJ, Lin CJ, Lee MJ, Liou HH. 
Complex haplotypic effects of the ABCB1 gene on 
epilepsy treatment response. Pharmacogenomics 
2005; 6:411-7. 
